Gérard Ber
Lantheus HoldingsAbout Gérard Ber
Dr. Gérard Ber (age 67) is an independent director of Lantheus Holdings, Inc. (LNTH) serving since June 2020; he sits on the Talent and Compensation Committee and the Science and Technology Committee . He co-founded Advanced Accelerator Applications S.A. (AAA) and served as its Chief Operating Officer until its acquisition by Novartis in January 2018, and previously served on the board of Progenics Pharmaceuticals, Inc. until LNTH acquired Progenics; he currently serves on the board of Evergreen Theragnostics, Inc. . Dr. Ber holds a doctorate from the Université of Pharmacy of Grenoble, France, and brings 30+ years of radiopharmaceutical product development, production, and commercialization experience .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Advanced Accelerator Applications S.A. | Co-Founder, Chief Operating Officer | 2002–Jan 2018 | Built and scaled molecular nuclear medicine operations; acquisition by Novartis AG |
| Progenics Pharmaceuticals, Inc. | Director | Nov 2019–2020 (until LNTH acquisition) | Board oversight through sale to LNTH |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Evergreen Theragnostics, Inc. | Director (Board Member) | Current | Radiopharmaceutical board role |
Board Governance
- Independence: The Board affirmatively determined that all directors except the CEO and Board Chair are independent under Nasdaq rules and Exchange Act Rule 10A-3; Dr. Ber is listed as independent .
- Committees: Member, Talent and Compensation Committee; Member, Science and Technology Committee .
- Board attendance and engagement: In 2024, the Board met 9 times; T&C met 8 times; Science and Technology met 4 times; each director (including Ber) attended at least 75% of Board and committee meetings on which they served. Non-employee directors meet in private executive session at the end of most Board meetings .
- Committee quality and interlocks: T&C Committee is entirely independent; no compensation committee interlocks or insider participation reported; members have never been officers/employees of LNTH .
Fixed Compensation
| Component | Amount | Notes |
|---|---|---|
| Annual Board retainer (member, cash) | $60,000 | Increased from $55,000 in April 2024 |
| Committee membership fees (cash) | T&C: $10,000; S&T: $7,500 | Chair fees: T&C $20,000; S&T $15,000 (Ber is a member, not chair) |
| 2024 Fees Earned or Paid in Cash (Ber) | $75,917 | Actual cash paid reflects prorations across the director term |
| Annual equity grant (fair value) | $400,000 | Program level; delivered as RSUs and options |
| 2024 Stock Awards (Ber) | $199,997 | RSUs granted in 2024 |
| 2024 Option Awards (Ber) | $199,992 | Options granted in 2024 |
Performance Compensation
| Award Type | Grant Date | Units | Vesting | Additional Terms |
|---|---|---|---|---|
| RSUs (director program) | May 9, 2024 | 2,635 | Vest on first anniversary of grant date (director program) | |
| Stock Options (director program) | May 9, 2024 | 4,853 | Vest on first anniversary of grant date (director program) |
- Performance metrics: LNTH’s director compensation uses time-based RSUs and options; no director-specific performance metrics (e.g., TSR, EBITDA) are disclosed for director awards .
- Stock ownership and retention: Directors must hold shares equal to 3x the annual cash Board retainer (excluding committee/chair retainers). Until achieving the guideline, directors must retain 50% of after-tax shares from vested equity. As of Dec 31, 2024, each director had achieved the requirement or was within the five-year compliance period .
Other Directorships & Interlocks
| Company | Type | Role | Potential Interlock/Notes |
|---|---|---|---|
| Evergreen Theragnostics, Inc. | Private/Other | Director | Radiopharmaceutical sector board; no LNTH-related transaction disclosed |
| Progenics Pharmaceuticals, Inc. | Public (historical) | Director | Served until LNTH acquired Progenics, creating an historical link to LNTH’s transaction |
- Committee interlock check: LNTH discloses no compensation committee interlocks for 2024, mitigating cross-directorship pay-setting risks .
Expertise & Qualifications
- Subject matter expertise: Listed for manufacturing/procurement/supply chain, sales and marketing, research and clinical development, risk assessment and management, and strategy development .
- Life sciences domain: Extensive radiopharmaceutical product development and commercialization experience, consistent with LNTH’s radiopharma focus .
- Public company governance: Experience includes prior public company board service; contributes to LNTH governance competence .
Equity Ownership
| Metric | Amount | As of | Notes |
|---|---|---|---|
| Beneficial ownership (shares) | 43,933 | Record date Mar 3, 2025 | Reported in beneficial ownership table |
| Unvested RSUs | 2,635 | Dec 31, 2024 | 2024 director grant unvested at year-end |
| Options outstanding | 30,200 | Dec 31, 2024 | Of which 4,853 unvested (2024 grant) |
| Stock ownership guideline | 3x annual Board cash retainer | Policy current | Directors must retain 50% of after-tax shares until meeting guideline; all directors either met or are within the 5-year compliance window |
| Hedging/pledging prohibition | Prohibited | Policy current | Covered by LNTH insider trading policy |
Governance Assessment
- Board effectiveness: Ber’s radiopharma operating background and functional expertise in manufacturing, clinical development, and risk management are well-aligned with LNTH’s strategy and product portfolio; his dual committee roles (Talent & Compensation; Science & Technology) indicate active engagement in human capital and technical oversight .
- Independence and attendance: Independent status is affirmed; 2024 attendance met LNTH’s minimum threshold, with frequent executive sessions supporting robust oversight .
- Alignment and incentives: Director pay mix is heavily equity-based (~84% of 2024 compensation), with strict stock ownership/retention guidelines and hedging/pledging prohibitions, enhancing shareholder alignment .
- Conflicts/related-party exposure: LNTH outlines a rigorous related person transaction approval policy under Audit Committee oversight; no Ber-specific related person transactions are identified in the proxy excerpts reviewed . T&C Committee reports no interlocks, reducing compensation governance risk .
- RED FLAGS: None observed in disclosed materials—no attendance shortfalls, no hedging/pledging, no option repricing, and no noted related-party transactions involving Ber .